Millipore Sigma Vibrant Logo

492031 NS8593 - CAS 875755-39-8 - Calbiochem

Overview

Replacement Information

Key Specifications Table

CAS #Empirical Formula
875755-39-8C₁₇H₁₇N₃

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
492031-10MG
Retrieving availability...
Limited Availability
Limited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 10 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewAn aminobenzimidazole derivative that selectively and reversibly blocks small conductance Ca2+-activated K+ channels (SK1-3; Kd = 420 nM, 600 nM, and 730 nM for SK1, SK2, SK3, respectively) in a Ca2+-dependent manner. It mediates channel gating by interacting with gating structures deep within the inner pore vestibule where Ser507 and Ala532 are deemed to be important for inhibition. Interacts at a site that is distinct from the apamin binding site in SK channels. Can access high-affinity binding sites from both the inside and outside of the cell membrane. Does not affect QT intervals, but prolongs the atrial effective refractive period and prevents acetylcholine-induced atrial fibrillations in ex vivo and in vivo models. Also shown to reversibly block TRPM7 channel (IC50 = 1.6 mM) in smooth muscle cells, primary podocytes, HEK293 cells expressing TRPM7, and ventricular myocytes in a Mg2+-dependent manner and blocks the motility of cells in culture.
      Catalogue Number492031
      Brand Family Calbiochem®
      Synonyms(R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine
      References
      ReferencesChubanov, V., et al. 2012. Brit. Journ. Pharm. 166, 1357.
      Jenkins, D., et al. 2011. Hypertension. 57, 1129.
      Jenkins, D., et al. 2011. Mol. Pharm. 79, 899.
      Jenkins, D., et al. 2011. Mol. Pharm. 79, 899.
      Lasse, S., et al. 2011. J. Cardiov. Pharm. 57, 672.
      Diness, J., et al. 2010. Circ Arrhythm Electrophusiol. 3, 380.
      Ji, H., et al. 2009. Eur. J. Neurosci. 9, 1883.
      Strobaek, D., et al. 2006. Mol. Pharm. 70, 1771.
      Product Information
      CAS number875755-39-8
      FormWhite powder
      Hill FormulaC₁₇H₁₇N₃
      Chemical formulaC₁₇H₁₇N₃
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalog Number GTIN
      492031-10MG 04055977273564

      Documentation

      NS8593 - CAS 875755-39-8 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      NS8593 - CAS 875755-39-8 - Calbiochem Certificates of Analysis

      TitleLot Number
      492031

      References

      Reference overview
      Chubanov, V., et al. 2012. Brit. Journ. Pharm. 166, 1357.
      Jenkins, D., et al. 2011. Hypertension. 57, 1129.
      Jenkins, D., et al. 2011. Mol. Pharm. 79, 899.
      Jenkins, D., et al. 2011. Mol. Pharm. 79, 899.
      Lasse, S., et al. 2011. J. Cardiov. Pharm. 57, 672.
      Diness, J., et al. 2010. Circ Arrhythm Electrophusiol. 3, 380.
      Ji, H., et al. 2009. Eur. J. Neurosci. 9, 1883.
      Strobaek, D., et al. 2006. Mol. Pharm. 70, 1771.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision17-August-2012 JSW
      Synonyms(R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine
      DescriptionAn aminobenzimidazole derivative that selectively and reversibly blocks small conductance Ca2+-activated K+ channels (SK1-3; Kd = 420 nM, 600 nM, and 730 nM for SK1, SK2, SK3, respectively) in a Ca2+-dependent manner. It mediates channel gating by interacting with gating structures deep within the inner pore vestibule where Ser507 and Ala532 are deemed to be important for inhibition. Interacts at a site that is distinct from the apamin binding site in SK channels. Can access high-affinity binding sites from both the inside and outside of the cell membrane. Does not affect QT intervals, but prolongs the atrial effective refractive period and prevents acetylcholine-induced atrial fibrillations in ex vivo and in vivo models. Also shown to reversibly block TRPM7 channel (IC50 = 1.6 mM) in smooth muscle cells, primary podocytes, HEK293 cells expressing TRPM7, and ventricular myocytes in a Mg2+-dependent manner and blocks the motility of cells in culture.
      FormWhite powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number875755-39-8
      Chemical formulaC₁₇H₁₇N₃
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesChubanov, V., et al. 2012. Brit. Journ. Pharm. 166, 1357.
      Jenkins, D., et al. 2011. Hypertension. 57, 1129.
      Jenkins, D., et al. 2011. Mol. Pharm. 79, 899.
      Jenkins, D., et al. 2011. Mol. Pharm. 79, 899.
      Lasse, S., et al. 2011. J. Cardiov. Pharm. 57, 672.
      Diness, J., et al. 2010. Circ Arrhythm Electrophusiol. 3, 380.
      Ji, H., et al. 2009. Eur. J. Neurosci. 9, 1883.
      Strobaek, D., et al. 2006. Mol. Pharm. 70, 1771.